Lifeline for cancer patients: rollover study extends access to promising drug
Disease control
Not yet recruiting
This study offers continued treatment with the drug RVU120 to people with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from it in an earlier study. Participants must have received at least 5 cycles of RVU120 and h…
Phase: PHASE2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated May 08, 2026 12:04 UTC